Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy Adults (VEE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03051386 |
Recruitment Status :
Active, not recruiting
First Posted : February 13, 2017
Last Update Posted : December 18, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Venezuelan Equine Encephalomyelitis Virus Disease | Biological: VEE Vaccine | Phase 2 |
This protocol is replacing NCT00582504.
The study population will consist of USAMRIID and qualified extramural participants who are at risk of exposure to VEE virus. This study will be performed at the USAMRIID SIP Clinic. This open-label study represents a continuation of previous research conducted at USAMRIID. Subjects will be vaccinated with 0.5 mL of VEE vaccine, Live, Attenuated TC-83, NDBR 102, Lot 4, Run 3 subcutaneously in the upper outer aspect of the triceps region. Subjects will contacted the following day and weekly for 4 weeks to assess for adverse events.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 500 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Phase 2 Open-Label Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis (VEE) Vaccine, Live Attenuated, Dried, TC-83, NDBR 102, Lot 4, Run 3, as Primary Vaccination in Healthy Adult Subjects at Risk of Exposure to VEE Virus |
Actual Study Start Date : | May 30, 2018 |
Estimated Primary Completion Date : | April 1, 2022 |
Estimated Study Completion Date : | April 1, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: VEE Vaccine
0.5 mL of VEE vaccine, Live, Attenuated TC-83, NDBR 102, Lot 4, Run 3
|
Biological: VEE Vaccine
0.5 mL of VEE vaccine administered subcutaneously in the upper outer aspect of the triceps region.
Other Name: TC-83 |
- Safety: Occurrence of Serious Adverse Events and Adverse Events (SAEs and AEs) [ Time Frame: 15 months ]Collect and assess safety data for VEE vaccine
- Safety: Percentage of subjects with symptoms following VEE vaccination [ Time Frame: 15 months ]Collect and assess safety data for VEE vaccine
- Safety: Percentage of subjects with each AE, system organ class of AE, severity, and association with vaccination [ Time Frame: 15 months ]Collect and assess safety data for VEE vaccine
- Immunogenicity: Percentage of subjects who develop titers of >1:20 [ Time Frame: 15 months ]Percentage of subjects who develop titers of ≥ 1:20 as determined by PRNT80 after VEE vaccination at each scheduled time point for which blood samples are taken and over the entire study period to study completion.
- Immunogenicity: Geometric Mean PRNT80 Titers of subjects [ Time Frame: 15 months ]Geometric mean PRNT80 titers of subjects at each scheduled time point for which blood samples are taken and over the entire study period to study completion.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Be 18-65 years old at time of consent.
- Have VEE virus PRNT80 < 1:10.
- If female of childbearing potential, must agree to have a serum pregnancy test on the same day before vaccine administration. (Exception: documented hysterectomy or ≥ 3 years of menopause.) The results must be negative. Females must agree not to become pregnant for 3 months after receipt of the vaccination.
- Be considered at risk for exposure to VEE virus and who have submitted a Request for IND Vaccines for the VEE vaccine.
- Sign and date the approved informed consent document and HIPAA Authorization.
-
Have in their charts:
- medical history (including concomitant medications) within 60 days of planned first administration of vaccine
- physical examination and laboratory tests within 1 year
- previous chest radiograph results and electrocardiogram
- Be medically cleared for participation by an investigator. Examinations or tests may be repeated at the discretion of the PI.
- Be willing to return for all follow-up visits.
- Agree to report any AEs that may or may not be associated with administration of the vaccine for at least 28 days after administration and agree to report all SAEs (for example, resulting in hospitalization) for the duration of the subject's participation in the study.
- Agree to defer blood donation for 1 year after receipt of the vaccine.
Exclusion Criteria:
- Have received VEE vaccine.
- Have family history (first degree relative) of diabetes mellitus (any type), a personal or family history of gestational diabetes, a confirmed elevated fasting serum glucose test (> 125 mg/dL), or a hemoglobin A1c > 5.6%. (At the principal investigator's discretion, a subject may participate if the family history of diabetes is only of late onset in an elderly parent.)
- Have clinically significant abnormal laboratory results (including evidence of hepatitis C, hepatitis B carrier state) or elevated liver function tests (two times the normal range or at the discretion of the PI).
- Have a personal history of an immunodeficiency or received treatment with an immunosuppressive medication, such as systemically administered glucocorticoids (eg prednisone) within 1 month before planned administration of the vaccine or with other immunosuppressive therapies within 6 months of planned administration of the vaccine. Other immunosuppressive therapies include all cancer chemotherapeutic agents, drugs to prevent transplant rejection, interferons, monoclonal antibodies, protein kinase inhibitors, methotrexate, TNF (tumor necrosis factor) inhibitors, and any other drug determined to be immunosuppressive by the PI. Current administration of topical, inhalational, or intranasal glucocorticoids is not excluded.
- Have confirmed HIV infection (antibody positivity).
- Have a positive pregnancy test or a breastfeeding female.
-
Have any known allergies to components of the vaccine:
- Neomycin sulfate
- Guinea pig heart cells
- Streptomycin
- Human serum albumin
- History of serious allergic reaction to guinea pigs or guinea pig products. (Subjects who have known allergies to guinea pigs will be evaluated. The vast majority of individuals who are allergic to guinea pigs are allergic to the dander from the animals. An individual with a past serious allergic reaction to guinea pigs will be excluded.)
- Have administration of another vaccine or investigational product within 28 days of VEE vaccination.
- Have any unresolved AE resulting from a previous immunization.
- Have a medical condition that, in the judgment of the PI, would impact subject safety.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03051386
United States, Maryland | |
Special Immunizations Program, Division of Medicine, USAMRIID | |
Fort Deterick, Maryland, United States, 21702 |
Principal Investigator: | Ronald B. Reisler, MD, MPH | USAMRIID |
Responsible Party: | U.S. Army Medical Research and Development Command |
ClinicalTrials.gov Identifier: | NCT03051386 |
Other Study ID Numbers: |
S-13-04 IND 142 ( Other Identifier: Food and Drug Administration ) M-10510 ( Other Identifier: IRB ) FY15-12 ( Other Identifier: USAMRIID ) |
First Posted: | February 13, 2017 Key Record Dates |
Last Update Posted: | December 18, 2019 |
Last Verified: | November 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Virus Diseases Encephalomyelitis, Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis Central Nervous System Infections Central Nervous System Diseases Nervous System Diseases Arbovirus Infections |
Encephalitis, Viral Central Nervous System Viral Diseases Alphavirus Infections Togaviridae Infections RNA Virus Infections Infectious Encephalitis Encephalitis Brain Diseases |